Adaptive Biotechnologies (ADPT) Competitors

Verona Pharma (NASDAQ:VRNA) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Does the media refer more to VRNA or ADPT?

In the previous week, Verona Pharma and Verona Pharma both had 5 articles in the media. Adaptive Biotechnologies' average media sentiment score of 1.04 beat Verona Pharma's score of 0.98 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verona Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in VRNA or ADPT?

85.9% of Verona Pharma shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by insiders. Comparatively, 6.2% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Do analysts recommend VRNA or ADPT?

Verona Pharma presently has a consensus price target of $53.14, suggesting a potential downside of 7.26%. Adaptive Biotechnologies has a consensus price target of $7.38, suggesting a potential downside of 4.84%. Given Adaptive Biotechnologies' higher possible upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Verona Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verona Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Adaptive Biotechnologies	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has better valuation and earnings, VRNA or ADPT?

Verona Pharma has higher earnings, but lower revenue than Adaptive Biotechnologies. Verona Pharma is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma	$460K	9,957.74	-$54.37M	-$1.92	-29.84
Adaptive Biotechnologies	$170.28M	6.72	-$225.25M	-$1.34	-5.78

Is VRNA or ADPT more profitable?

Verona Pharma has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -110.13%. Adaptive Biotechnologies' return on equity of -62.06% beat Verona Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verona Pharma	N/A	-79.54%	-43.49%
Adaptive Biotechnologies	-110.13%	-62.06%	-26.82%

Does the MarketBeat Community favor VRNA or ADPT?

Verona Pharma received 233 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 80.79% of users gave Verona Pharma an outperform vote while only 57.23% of users gave Adaptive Biotechnologies an outperform vote.

Company	Underperform	Outperform
Verona Pharma	Outperform Votes 328 80.79%	Underperform Votes 78 19.21%
Adaptive Biotechnologies	Outperform Votes 95 57.23%	Underperform Votes 71 42.77%

Which has more volatility & risk, VRNA or ADPT?

Verona Pharma has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Summary

Adaptive Biotechnologies beats Verona Pharma on 9 of the 17 factors compared between the two stocks.